Drug Trial Radar · NCT04624659
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Jan 29, 2021
Primary completion
Feb 6, 2026
Study completion Mar 19, 2027
Sponsor
- Lead sponsor
- Forma Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- This study is currently undergoing a sponsor transition from Forma to Novo Nordisk. Sponsor field will be updated once the transition is complete.
- First posted
- Nov 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).
Conditions
- Sickle Cell Disease
Interventions
Etavopivat Tablets Low doseDrug
200 mg once daily
Etavopivat Tablets High doseDrug
400 mg once daily
Placebo TabletsDrug
Placebo once daily
Etavopivat TabletsDrug
Selected dose once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hemoglobin response rateTime frame: 24 Weeks
- Annualized vaso-occlusive crisisTime frame: 52 Weeks
Locations
142 sites in 17 countries. Site status is shown where the registry gives one.
Univ of Alabama Birmingham
Birmingham, Alabama
Phoenix Children's Hsptl
Phoenix, Arizona
[Legal] Woodland International Research Group, LLC
Little Rock, Arkansas
[Legal] Collaborative Neuroscience Network, LLC
Long Beach, California
Pacific Research Partners
Oakland, California
UCSF Oakland Benioff ChildHosp
Oakland, California
University Of California Irvine
Orange, California
UC Davis Medical Center
Sacramento, California
University of Connecticut
Farmington, Connecticut
Yale University
New Haven, Connecticut
Children's National Health Hospital
Washington D.C., District of Columbia
Howard University
Washington D.C., District of Columbia
Cornerstone Research Institute
Altamonte Springs, Florida
University of Florida
Gainesville, Florida
Foundation for Sickle Cell Disease Research
Hollywood, Florida
University Of Miami
Miami, Florida
Advanced Pharma CR
Miami, Florida
Arnold Palmer Children's Hospital
Orlando, Florida
Emory University School of Medicine
Atlanta, Georgia
Sonar Clinical Research
Atlanta, Georgia
Children's Healthcare of Atlanta Investigational Medication Pharmacy
Atlanta, Georgia
Center for Blood Disorders Augusta University
Augusta, Georgia
iResearch Atlanta, LLC
Decatur, Georgia
University of Illinois at Chicago
Chicago, Illinois
Children's Hosp-New Orleans
New Orleans, Louisiana
University Of Maryland School of Medicine
Baltimore, Maryland
Massachusetts General Hospital_Boston
Boston, Massachusetts
Boston Medical Center
Boston, Massachusetts
[Legal] Dr. Vince Clinical Research, LLC and Dr. Vince Clinical Research, P.A.
Detroit, Michigan
Karmanos Cancer Institute
Detroit, Michigan
Washington University School of Medicine_St. Louis
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
NYC Health+Hospitals
Brooklyn, New York
Queens Hospital Center
Jamaica, New York
North Shore Long Island Jewish Medical Center
New Hyde Park, New York
Columbia University Medical Center_New York
New York, New York
Weill Cornell Med Coll-NYPH
New York, New York
Jacobi Medical Center
The Bronx, New York
Montefiore Medical Center
The Bronx, New York
[Legal] The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Showing 40 of 142 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.